Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To evaluate the role of autologous and allogenic stem cell transplantation with
Campath-1H for patients with peripheral T-cell lymphoma (PTCL).
2. To examine the impact of in-vivo purging with Campath -1H pre-autologous stem
transplantation for patients with PTCL.
3. To evaluate the impact of soluble CD52 upon in-vivo purging with Campath-1H.
4. To evaluate the role of Campath -1H in the treatment minimal residual disease after
autologous transplantation for PTCL.